BioCentury | Aug 27, 2020
Distillery Therapeutics

Retrotransposons as acute myelogenous leukemia targets

DISEASE CATEGORY: Cancer INDICATION: Acute myelogenous leukemia (AML) Targeting LTR2B and the related LTR2, both long terminal repeat retrotransposons, could treat AML by reducing expression of the lipoprotein component APOCI. Analysis of a The Cancer...
BioCentury | Aug 21, 2020

Aug. 20 Quick Takes: Funding for Alzheon’s Alzheimer’s Phase III; plus Merck, FDA guidance, LumiraDx, RACE for Children, blood plasma and Novo-Evotec

Alzheon preps trial with $47M grantNIH’s National Institute on Aging (NIA) will provide $47 million to Alzheon Inc. over five years to conduct a Phase III study of ALZ-801 to treat early Alzheimer’s disease in...
BioCentury | Jun 11, 2020

With $725M Corvidia takeout, Novo gets clinical atherosclerosis asset

Novo Nordisk’s deal to acquire Corvidia for $725 million up front gives the Danish pharma a Phase IIb atherosclerosis asset that expands its range in cardiometabolic diseases adjacent to its core business of treating diabetes...
BioCentury | Jun 10, 2020
Emerging Company Profile

With $50M from Versant, Lycia takes targeted degradation outside the cell

Fourteen months after leading biochemist Carolyn Bertozzi published a preprint on a new class of compounds that degrade extracellular proteins inaccessible to PROTACs, Versant-built Lycia has emerged with $50 million to turn that technology into...
BioCentury | Jun 6, 2020
Translation in Brief

Engineered bacteria for targeted bacterial killing; plus Cas12a base editors, base editing to restore hearing and more

Targeted delivery of antibacterial toxins University of Washington researchers have co-opted a bacterial secretion system to enable killing of select bacterial species. They d escribed in Cell Host & Microbe how they programmed bacteria with...
BioCentury | Feb 15, 2020
Translation in Brief

COVID-19 therapy from Emory and diagnostic from Sherlock co-founders; plus Genentech, Homology and more

Emory, UNC to test nucleoside analog against COVID-19 The Emory Institute for Drug Development and University of North Carolina at Chapel Hill are conducting preclinical studies of nucleoside analog to treat COVID-19, an Emory University...
BioCentury | Feb 11, 2020
Product Development

Alzheimer’s prevention replays the same amyloid failures as the treatment setting

The Phase II/III DIAN-TU trial of Lilly’s solanezumab and Roche’s gantenerumab was always a long shot, given the previous late-stage failures of both agents in Alzheimer’s trials. Perhaps more surprising is that both compounds remain...
BioCentury | Feb 7, 2020
Translation in Brief

Gilead’s remdesivir vs. 2019-nCov in cells; plus Syndax, Syntrix and Max Planck

Chinese team provides data for Gilead’s remdesivir against 2019-nCoV A group from the Chinese Academy of Science’s Wuhan Institute of Virology and the Beijing Institute of Pharmacology and Toxicology showed that remdesivir reduced 2019-nCoV infection...
BioCentury | Jan 23, 2020
Clinical News

Akcea, Ionis Phase II hypertriglyceridemia data hint at improved safety for conjugated antisense therapy

Akcea and Ionis announced plans to develop AKCEA-APOCIII-LRx for familial chylomicronemia syndrome based on Phase II safety and efficacy results from hypertriglyceridemia patients. It gives the companies a second shot at marketing an APOC-III antisense...
BioCentury | Dec 21, 2019
Company News

Dec. 20 Company Quick Takes: Genmab partners with CureVac; plus pair of Biogen deals, Ionis, Akcea-Novartis, Paratek and J&J-Taris

CureVac, Genmab to develop RNA-encoded antibody Genmab A/S (NASDAQ:GMAB; CSE:GMAB) and CureVac AG have partnered to discover an mRNA-encoded antibody candidate to treat cancer. Genmab will pay $10 million up front and invest €20 million...
Items per page:
1 - 10 of 812